Context: Measurement of plasma fractionated metanephrines has been proposed as a highly sensitive test for the detection of pheochromocytoma. Chromogranin A (CgA) is oversecreted in pheochromocytoma. Simultaneous detection of CgA and fractionated metanephrines could improve the diagnostic efficacy in this rare disease. Objectives: The objective of this study was to precise the diagnostic efficacy in pheochromocytoma by simultaneous testing of serum CgA and plasma metanephrines. Design: We studied a group of 24 hypertensive patients suspected of pheochromocytoma after their admission at the National Institute of Endocrinology from Bucharest. Plasma fractionated metanephrines were assayed by enzyme immunoassay. Serum chromogranin A was assayed by enzyme linked immunosorbent assay.
PF.2. The diagnostic performance of plasma and urinary fractionated metanephrines to confirm pheochromocytoma in a hypertensive selected group Context: Plasma fractionated metanephrines provide a highly sensitive test for excluding or confirming pheochromocytoma, but sometimes these tests may fail to detect this rare tumor. Urine fractionated metanephrines could be useful in these situations and plasma and urine simultaneous metabolites detection could improve diagnostic pheochromocytoma efficacy. Objectives: The objective of this study was to test the diagnostic efficacy by concomitant detection of plasma and urine fractionated metanephrines in a selected hypertensive group.
Design: A group of 62 patients was admitted at the National Institute of Endocrinology from Bucharest over one year. Plasma and urine samples collected were subject to enzymatic immunoassays for fractionated metanephrines. Results: Of 62 patients, pheochromocytoma was confirmed in 12 patients and excluded in 50 patients. Free plasma normetanephrines (NMNp) were increased in 11 patients with a positive predictive value: 0.811 (CI: 0.460-0.975) and free plasma metanephrines (MNp) were greater in 10 patients with a positive predictive value: 0.796 (CI: 0.516-0.979). Urine conjugated normetanephrines
The current project aims to establish a newly developed high sensitive ELISA for the measurement of free metanephrines in the plasma of patients in the work-up for pheochromocytoma. Clinical data and plasma samples from 42 hypertensive patients (21 female, 21 male; mean age 50 years, range 22-82) and 104 normal volunteers were collected and analysed. After an overnight fast plasma samples were collected on ice in EDTA-and heparin-coated tubes. Plasma metanephrines were measured by a newly developed ELISA from IBL, Hamburg, Germany. After protein precipitation and acylation the metanephrines are measured by competitive ELISA. When the system is in equilibrium, the free biotinylated antigen is removed by a washing step and the antibody bound biotinylated antigen is determined by use of newly developed streptavidin-peroxidase as marker and TMB as substrate.The assay, calibrated with the biologically active L (À) forms, showed good agreement with the formerly developed RIA of r 2 greater than 0.95 for both metanephrine and normetanephrine. The RIA has good agreement with the LC-MS/MS method for normetanephrine (r 2 ¼ 0.97) and for metanephrine (r 2 ¼ 0.98). Both specimen, EDTA and heparin plasma, can be used with the same results. The ELISA has a good precision of below 15% in concentrations covered by the whole standard curve. Measurements in 5 patients with pheochromocytoma revealed elevated plasma concentrations for free metanephrine/normetanephrine preoperatively and values within the normal range after tumor removal. Our data suggest a high validity of the newly developed ELISA for measuring free metanephrines in both EDTA and heparin plasma. Objectives: The aim of this study was to determine the sensitivity and specificity of urinary catecholamines, plasma metanephrines and chromogranine A, at Karolinska University Hospital. Design: Retrospective study. Methods: Two groups of patients were included; one control group of 19 patients with arterial hypertension or incidentaloma, and a group of 26 patients with histologically proven pheochromocytoma (22 patients) and paraganglioma (4 patients), all treated at Karolinska University Hospital in between [2003] [2004] [2005] [2006] [2007] . Full clinical data was obtained from the patients; median age 60 years (19-83 years), 15 women and 11 men, median tumour size 6.5 cm (3.5-12 cm) and median follow up time 19 months (2-51 months). Results: In the control group urinary catecholamines, plasma metanephrines and plasma chromogranin A gave false positive results in 53, 37 and 17%, respectively. In the disease group the sensitivity was 95, 100 and 88%, respectively. Three patients with recurrent disease were diagnosed with elevated urinary catecholamines and plasma metanephrines. Conclusion: In our study the plasma metanephrines showed the highest sensitivity however with a very low specificity (63%) compared to many other publications, the latter was more marked using urinary catecholamines. The assay of chromogranin A was less sensitive but more specific in diagnosing pheochromocytoma with present cut-offs levels. The optimal diagnostic threshold for plasma metanephrines and urinary catecholamines needs to be adjusted to better balance between sensitivity and specificity in a large cohort of patients who are investigated because of clinical signs suggestive of a pheochromocytoma.
PF.5. An analysis of biochemical diagnosis of pheochromocytoma and paraganglioma
PF.6. Proficiency test of plasma free and total metanephrines: report from a study group
Objective: Establish an external quality assessment scheme (EQAS) to allow direct comparisons between all laboratories that measure free and total (free þ sulfoconjugated) metanephrines. Methods: A pilot study was initiated in 10 selected centres for plasma free and total metanephrines. Serum and citrated plasma were prepared by RECIPE, a diagnostic company, experienced in manufacturing lyophilized quality controls. The samples were also spiked with metanephrines and shipped by PROBIOQUAL, a centre that organizes EQAS. The survey provided 1 result for free metanephrines in plasma by RIA, 1 by LC-MS and 5 by LC-ECD while for total metanephrines 1 report by LC-MS and 4 by LC-ECD was received. Results and discussion: The dispersion of concentrations observed with free normetanephrine (NMN) and metanephrine (MN) ranged from 20.2 to 34.4% with no differences between serum and plasma. After excluding the one immunoassay the dispersion ranged from 10.9 to 30.7% The overall recovery of spiked samples was similar for free NMN and MN and between the two matrices used for the study (75-87%). The dispersion of concentrations of total NMN and MN at 25-43.5% was higher than those observed with free metanephrines. Recoveries of spiked NMN and MN were erratic probably due to the relative low amount of free metanephrines spiked in samples, representing less than 10% of the absolute concentration of endogenous total metanephrines. In conclusion, we set-up an EQAS that allows laboratories to control their uncertainty for the determination of plasma free and total metanephrines.
PF.7. Accuracy of plasma and urinary metanephrines measured by a newly developed ELISA and of serum chromogranin A for the diagnosis of pheochromocytoma Introduction: Plasma and urinary metanephrines determined by a newly available ELISA as well as serum chromogranin A (CgA) were evaluated for the diagnosis of pheochromocytoma. Methods: Spontaneous blood samples and 24 hurine samples were collected in 133 subjects, including 19 histologically proven pheochromocytomas, 13 aldosterone-secreting and 20 cortisolsecreting adrenal adenomas, 27 nonfunctioning adrenal masses, 15 patients with essential hypertension and 39 healthy normotensive volunteers.
Plasma and urinary metanephrine (MN) and normetanephrine (NMN) as well as CgA were determined and putative thresholds calculated by ROC analysis. Results: Plasma NMN showed highest sensitivity (89.5%) and specificity (98.3%) using a threshold of 167 pg/ml, with lower sensitivity (85.7%) and specificity (91.8%) for urinary NMN by a threshold of 318 mg/24 h. Plasma and urinary MN demonstrated a much lower sensitivity (68.4% resp. 71.4%) and specificity (90.0% resp. 77.6%) using a threshold of 26 pg/ml and 89 mg/24 h respectively. Recently, nuclear genes encoding two mitochondrial complex II subunit proteins, SDHD and SDHB, have been found to be associated with the development of familial pheochromocytomas and paragangliomas (Hereditary pheochromocytoma/paraganglioma syndrome: HPPS). Growing evidence suggest that mutation of SDHB is highly associated with abdominal (or thoracic) paraganglioma and the following distant metastasis (malignant paraganglioma). However, these findings were obtained mainly from USA and Europe. Therefore, it remains uncertain whether SDHB plays a pathological role in populations outside these geographic locations. In the present study, we sequenced the entire coding region of the SDHB gene from 16 malignant pheochromocytomas derived from Japanese subjects. Consequently, analysis of blood taken from 16 cases of malignant pheochromocytomas (7 abdominal paraganglioma and 9 adrenal pheochromocytomas) led to the identification of three SDHB mutations. It should be noted that 4 SDHB mutations were detected in 7 abdominal paraganglioma-derived malignant cases (4/7), whereas 1 SDHB mutation was observed in 9 malignant cases derived from adrenal pheochromocytoma (1/9), in agreement with previous reports. Further studies are required to establish the clinical significance of SDHB genetic testing in Japan, especially for malignant cases. Von Hippel-Lindau (VHL) disease is a hereditary tumour syndrome manifested by haemangioblastomas, clear cell renal cell carcinomas and phaeochromocytomas. Although these aforementioned tumours are the hallmarks of VHL, a multitude of other rare tumours can occur and even be the sole manifestation of the disease. One of these rare tumours is parasympathetic paraganglioma (pPGL). The occurrence of pPGL in VHL has been described in the literature in 3 cases, but the involvement of the VHL tumour suppressor gene has never been proven in tumour tissue.
Here we present a case of a 23-year-old female patient with a non-functional paraganglioma near the left carotid, discovered at a routine check-up for her known VHL disease. No other clinical manifestations were detected thus far. Mutation analysis of the tumour revealed a missense mutation (R64P) in the VHL-gene and revealed loss of chromosome 3p. Direct sequencing of the VHL-gene showed complete loss of the wild type allele indicating that this tumour has to be considered in the context of VHL disease. Germline mutation revealed the same R64P mutation. No germline mutations were found in the SDHB, C and D genes. This finding, together with previously reported cases in the literature, suggests that pPGL do occur in the context of VHL disease and that screening protocols should be directed at the timely discovery of such lesions.
PF.14. Low penetrance of symptomatic or occult phaeochromocytoma/paraganglioma in a large kindred of subjects with a point mutation ( 268 C4T) in exon 3 of the SDHB gene Results: Seventeen large deletions were found (5.2%): 7 in the SDHB, 5 in the SDHD, 2 in the SDHC and 3 in the VHL genes. All patients with large deletions present one or more specific clinical criteria such as malignancy (5/17), family history (4/17), syndromic presentation of VHL disease (3/17) and/or young age of onset (10/17). Conlusion: These methods should be routinely applied when the classical mutation screening is negative, in particular for patients with clinical criteria suggesting a high probability of VHL-or SDHs-linked genetic disease. We recently described a recessively-inherited Multiple Endocrine Neoplasia syndrome in the rat (MENX), in which affected animals develop pheochromocytoma with 100% penetrance. The adrenal lesions progress from hyperplasia to tumor with time. To improve our understanding of the molecular basis of pheochromocytoma development and progression we performed gene expression profiling of lesions at discrete stages of progression. We analyzed 8 hyperplastic lesions, 10 pheochromocytomas and 4 pooled age-and sex-matched normal adrenals using the Affymetrix Rat 230v2.1 microarrays. Gene expression levels were estimated using the robust multiarray analysis (RMA) method after quantile normalization and background correction. To identify differentially expressed genes between affected and normal tissues we performed gene filtering using SAM (Significance Analysis of Microarrays) analysis. Using a cut-off of more than 2-fold difference, expression profiling of hyperplastic lesions identified 358 up-and 265 down-regulated genes compared to normal tissue, whereas that of tumors identified 411 up-and 431 down-regulated genes. Preneoplastic and neoplastic lesions share about one fourth of the 100 most differentially expressed genes (both up-or down-regulated compared to normal tissues), indicating that these alterations are early determinants of pheochromocytoma development. Eight genes up-regulated in both types of lesions were selected for validation by quantitative RealTime RT-PCR. Cdkn2A (p16), Cdkn2C (p18), Sctr, Cxcr4, Neurod1, Gal, Dgkh, Pqbp1 were up-regulated by 2-150-fold over normal tissue in the lesions used for the array analyses and in additional ones. We show here that defined gene expression changes are associated with syndromic pheochromocytoma in the rat.
PF.20. Molecular signatures associated with pheochromocytoma development
The majority of pheochromocytomas are benign, but approximately 10% are recognized as malignant forms. It is however difficult to clinically and histopathologically distinguish between benign and malignant cases. The only indisputable proof of malignancy is the presence of metastases. Approximately 10-25% of all tumours present as a component of inherited cancer syndromes. The vast majority of pheochromocytoma is then considered to be sporadic and the genetic mechanism(s) underlying the development of these tumors is largely unknown. The rationale in the present project is to use a genomic microarray with full coverage of the human genome consisting of more than 32 000 overlapping BAC clones to elucidate the genetic events leading to sporadic forms of pheochromocytoma as well as detect alterations more common in the malignant cases. Nearly 90 tumour and blood samples from patients are included in the study (manuscript in preparation). Results show that loss of chromosome arm 1p is the most frequent chromosomal alteration in both benign and malignant cases. Loss of 3q, 22q and 17p are also common events as well as monosomy 11. Gains were significantly overrepresented in the malignant tumours, especially on chromosome 19 and 20. Trisomy 5 and 12 were also frequently detected. Furthermore, malignant tumours present in general with higher number of aberrations than the benign cases. Owing to the high resolution of the method used we were able to define narrow regions of DNA copy number changes encompassing interesting candidate tumour suppressor genes and oncogenes possibly involved in the tumourigenesis of pheochomocytoma.
PF.22. RET exon 13 germline polymorphism in patients with pheochromocytoma and paraganglioma tumors
Germinal mutations in protoncogene RET are associated with the inherited medullary thyroid carcinoma which occurs as a sole manifestation of disease or, more frequently as a part of multiple endocrine neoplasia (MEN 2). The contribution of RET polymorphism to the occurrence of apparent sporadic medullary thyroid carcinoma is controversial. In our previous study we have found out that the frequency of RET 769 CTT4CTG polymorphism in patients with medullary thyroid carcinoma is not significantly higher when compared to control group.
In the present study we analyzed the same polymorphism in 113 patients with apparent sporadic pheochromocytomas or paragangliomas, in whom known germline RET, VHL and SDHB-D mutations were excluded. 180 patients with sporadic medullary cancer and 90 healthy control subjects were included. DNA was isolated from peripheral blood leucocytes. Polymorphism 769 CTT4CTG was found in 45 patients (40%). Its frequency was 40% in patients with pheochromocytomas and 43% in the group of paragangliomas. Simultaneously, its frequency was 23% in patients with true sporadic medullary thyroid carcinoma and 27% in the control group of healthy blond donors (Po0.05). Introduction: Studies of patients with pheochromocytoma/paraganglioma (PC/PG) and sporadic presentation have indicated germ-line mutations (VHL, RET, SDHB and SDHD) in up to 24%. We have estimated this frequency in a population-based study of PC/abdominal PG in West Sweden. Patients and methods: PC/abdominal PG are recorded in the National Cancer Register since 1958. In our region (1.7 mill. inhabitants) 187 cases are reported (not including 58 post-mortem diagnoses). 122 patients had sporadic presentation, 15 MEN-2, 10 NF-1, 1 VHL, and 1 Carney syndrome. In 38 deceased patients detailed information was lacking. 77 patients with sporadic presentation were alive and invited to screening; 68 accepted. Bi-directional sequencing was performed of SDHB exon 1-8, SDHD exon 1-4, VHL exon 1-3 and in selected cases RET exon 10, 11, 14 and 16.
Conclusion
Results: Out of the 68 patients 42 had a risk factor (low age, bilateral, multifocal, or malignant disease) vs 6/9 among non-participants and 14/45 among deceased patients with sporadic presentation. In SDHB 4 missense mutations (487T4C n ¼ 2, 716C4G and 725G4A) and 1 splice-site mutation (IVS4 þ 1G4A) were found; 3 had low age as risk factor. No mutations of SDHD, VHL or RET were found, i.e. the mutation frequency was 7.4%. No patient with SDHB mutation has developed a malignant phenotype during a mean/median followup of 22/25 years. Conclusion: This population-based study of PC/abdominal PG with sporadic presentation showed a lower mutation frequency (7.4%) than previously reported despite a high proportion of risk factors. All mutations were seen in SDHB with no observed malignancy.
PF.24. Study on the genetic mutations of succinate dehydrogenase (SDH) in pheochromocytoma
Zheng-pei Zeng, Ya-ru Zhou, Jing Zhang, An-Li Tong, Lin Lu, Shi Chen, Wei Liang, Han-zhong Li, Yuan-jia Chen Peking Union Medical College Hospital, Beijing, China Objective: Detect gene mutation and loss of heterozygosity (LOH) and microsatellite instability (MSI) for SDHB and SDHD in pheochromocytoma (PHEO) patients. Methods: 12 pairs of primers were used to amplify 8 exons of SDHB gene and 4 exons of SDHD gene. SDHB and SDHD gene mutations were detected in 63 PHEO patients, 22 kindreds of familial PHEO and 20 normal controls by PCR-SSCP and PCR products directly sequence, respectively. With a-P 32 -dCTP cooperated into the reaction volume, we spanned 1p35-p36 (SDHB locus) and 11q23 (SDHD locus) LOH in paired samples of DNA extracted from tumor tissues and peripheral blood leukocytes of 40 PHEO patients. Results: Two cases (2/63, 3.2%). of sporadic extra-adrenal paraganglioma (PGL) were shown as SDHB gene mutations, which present in exon 7. One is missense mutation: g.692 G 4A, causing amino acid Arg231His another is deletion mutation: g.760delT, causing amino acid Cys254Val 258X. No gene mutation in SDHD was identified in 63 patients. 42.9% cases (15/40) with extra-adrenal tumors were shown as 1p35-p36 LOH (1 case as 1p35-p36 MSI). 2 cases (2/40) with malignant extra-adrenal tumors had 11q23 LOH (2 cases as 11q23 MSI). Conclusion: we detected two novel SDHB gene mutation in patients with extra-adrenal PGL, but no mutation in SDHD gene. SDHB gene mutation, 1p35-p36 LOH and 11q23 LOH/MSI could be used as potential genetic markers to detect malignant and extra-adrenal PGL at early stage.
PF.25. Lack of evidence that EGLN3/PHD3 gene mutations are involved in the development of pheochromocytoma/paraganglioma L Mori, M Giacchè, R Tosini, O Patrizi, C Cappelli, E Gandossi, E Agabiti Rosei and M Castellano Molecular Medicine Laboratory and Endocrinology Unit, Brescia University Medical School, Brescia, Italy
It has been recently proposed that the gene EGLN3/ PHD3 could be involved in the development of pheochromocytoma/paraganglioma (PHEO/PGL) syndrome. In fact, this protein has a key downstream position with respect to the pathway where VHL, RET, NF1 and SDHx genes are involved. We designed this study with the aim of investigating genetic variability of EGLN3/PHD3 in PHEO/PGL patients. Forty-one sporadic PHEO-PGL were examined; all these patients resulted negative for point mutations in a previous screening conducted on VHL, SDHX and RET genes.
The five exons of EGLN3 were fully examined by direct sequencing. We found a single nucleotide deletion (À/A) in intron 4, corresponding to a previously described SNP (rs3832940). Seventeen out of 41 patients carried the deletion allele. No other SNP reported in GENBANK and ENSEMBL databases was observed in this sample, and no previously unreported genetic variants were found at this screening. The present findings seem to exclude a major role of EGLN3 gene variability in the pathogenesis of PHEO/PGL, although the occurrence of functionally relevant intronic variants and/or mutations in the regulatory regions cannot be excluded.
PF.26. Genetic screening of large SDHx and VHL deletions in pheochromocytoma/ paraganglioma patients: an Italian study Point mutations or short insertions/deletions affecting VHL and SDH genes are the more frequent alterations identified in genetic screening of phecochromocytoma/paraganglioma patients (PHEO/ PGL). However, the methods generally adopted for these screenings, such as direct sequencing, DHPLC or SSCP, are insufficient to identify all the potential genetic variants. In fact, it is not possible to exclude mutations in regulatory regions, large deletions of the entire gene or exon skipping promoted by Alu sequences. This study was aimed to investigate the frequency of large deletions of SDHX and VHL genes in a cohort of Italian patients with apparently sporadic pheochromocytoma/paraganglioma (PHEO/PGL). Genomic DNA samples from 44 PHEO-PGL were examined; all these patients resulted negative for point mutations in a previous genetic screening. MLPA technique (MRC-Holland) was applied on SDHB, C D and VHL genes; SDHB was also investigated by multiplex-PCR. The analysis with the multiplex-PCR detected two patients carriers of presumable deletions regarding the exon 1 of SDHB; however, subsequent semiquantitative real-time PCR was not able to identify any gross deletion in this exon. Similarly, MLPA did not confirm the positive results obtained by multiplex-PCR and moreover did not find any other variation in the remaining SDH subunits and VHL genes. We conclude that the prevalence of large deletions in Italian PHEO/PGL is presumably low. Our data do not directly support the superiority of any screening technique (MLPA vs multiplex-PCR) but underline the opportunity to validate any positive finding with an alternative method.
of the RET proto-oncogene in MEN 2. Germline mutations within one of the 3 exons are responsible for the majority of VHL cases. We determine mutations from sporadic or familial PHEOs patients if it was similar to those in MEN 2 or VHL disease. Methods: 51 cases of sporadic PHEO and 6 familial PHEO were analysis for mutations of RET 10, 11, 13, 14, 15, 16 exons and the entire coding sequence of VHL. Genomic amplicons encompassing 10, 11, 13, 14, 15, and 16 exons of RET proto-oncogene and the entire coding sequence of VHL were created by PCR. Its products were purified and analysis by direct sequence analysis.
Results: 8/51 sporadic PHEO were shown as RET mutations within exon 11 (4 adrenal PHEO and 4 extra-adrenal PHEO). There were 4 patients with malignant PHEO among them. RET mutations of exon 11 were found in 13 PHEO cases. No VHL mutations were detected in sporadic PHEO. There were 2 families which shown point mutation of VHL gene.
Conclusions:
The ratio of mutation in the RET protooncogene was 15.7% from sporadic PHEO which was higher in malignant than in benign tumors. The RET and VHL mutations should be detected in patients and their first relatives.
PF.28. Prevalence of genetic mutations in nonsyndromic pheochromocytoma or functional paraganglioma-experience from the Czech Republic Objective: To investigate expression of vascular endothelial growth factor (VEGF), pvon Hipple-Lindau (pVHL), hypoxia-inducible factor 1a (HIF-1a) and hypoxia-inducible factor 2a (HIF-2a) in PHEO tumors by immunohistochemical staining. Methods: The specimens of 34 cases sporadic PHEO (27 benign, 9 malignant) and 6 cases of familial PHEO were investigated. Envision two steps were used for VEGF, pVHL, HIF-1a and HIF-2a staining. Semi-quantitative point scores for VEGF, pVHL, HIF-1a and HIF-2a staining. Calculated as the percentage and intensity of staining: low expression was defined as 0-3 point scores, and high expression was 4-6 point scores. Compare the difference of VEGF, pVHL, HIF-1a and HIF-2a expression among normal adrenal gland and PHEO tumors. Results: pVHL expression was lower and HIF-1a expression was higher in PHEO with LOH of VHL gene than that without LOH of VHL gene, respectively, (Po0.05). HIF-2a and VEGF expression was higher in PHEO than normal adrenal gland tissue (Po0.05).
Background: Here we report for the first time the potential relationship of the studied populations in Freiburg-Warsaw registry. Material and Methods: In 232 patients with pheochromocytoma and/or paraganglioma registered in Polish population we identified 15 (6, 5%) patients with PGL1 syndrome. 12 pts (80%) carried the same type of SDHD gene mutation (c.33 C4A, p.C11X). We found 4 cases with this mutation in German population and 3 relatives. Finally there were 19 patients (12F, 7 M), mean age: 31±14 years. Results: Analysis revealed a common haplotype segregating with the mutation between the apparently unrelated families. The estimated low frequency of the latter in normal population strongly suggested that all patients carry a common ancestral mutation. Pheochromocytoma was the first manifestation in 8 patients (42%), head and neck paraganglioma in 11 cases (58%). In patients with pheochromcytoma there were: extraadrenal tumors in 5 cases (63%), adrenal tumors in 4 patients (50%), bilateral adrenal tumors in 1 case (12%) and thoracic tumors in 1 case (5%). Multiple tumors were found in 16 patients (84%), thoracic localization of the tumor was found in 6 cases (32%). Recurrence was observed in 13 patients (69%). Head and neck parangliomas penetration was estimated on 72%±11 by the age of 40. Malignant pheochromocytoma was found in one patient. Conclusion: In SDHD c.33 C4A, C11X mutation carriers high incidence of multiple, extraadrenal abdominal and thoracic tumors is noted. Case of malignancy and high incidence of recurrence give reason for careful screening of these patients.
PF.33. Long-term culture of bovine chromaffin precursor cells V Vukicevic, L Gebauer, G Eisenhofer, KF Chung, SR Bornstein and M Ehrhart-Bornstein Molecular Endocrinology, MTZ, Dresden, Saxsony, Germany Chromaffin cells and sympathetic neurons derive from a common sympathoadrenal progenitor cell. Unlike sympathetic neurons, chromaffin cells are able to proliferate throughout life. In this study, potential dynamic changes in long-term cultures of bovine chromaffin cell progenitors (CS) were characterized. Similar to neuronal progenitors, isolated chromaffin cells formed chromospheres (CS) able to proliferate in a low-attachment environment. They expressed several progenitor markers including nestin and Sox1. The capability of progenitor cells for self-renewal and to form CS depended on the density of seeding. An increased sphere initiation capacity over 4 weeks of culturing was observed, suggesting enrichment of progenitor cells. Cell cycle analysis showed no tetraploid cells in G2/M phase, indicating preserved chromosomal stability. Additionally, relative telomere length remained constant over 8 weeks of culturing, pointing towards absence of an eventual senescence crisis and emphasizing overall stability of CS culture. HPLC analysis indicated maintenance of epinephrine production with a tendency to increased dopamine production. Chromaffin cells from adrenal medulla are the main source of epinephrine and norepinephrine which play an important role in the body's stress response. Unlike the closely related sympathetic neurons, which also develop from neural crest during embryogenesis, chromaffin cells are able to proliferate throughout the whole life. This suggests the existence of chromaffin cell progenitors in the adrenal medulla. Therefore, the aim of this study is to isolate and to characterize adrenal medullary chromaffin progenitors. Bovine chromaffin cells were isolated by collagenase/DNase digestion, differential plating and cultured in low-attachment conditions. Similar to neurospheres, chromaffin cells formed spheres and were further referred to as chromospheres. Chromospheres not only showed BrdU incorporation and self-renewal ability, they also expressed progenitor markers including Nestin and Sox1. Through the selection in low-attachment environment and the formation of chromospheres, the expression of PNMT mRNA, which catalyzes the last step in epinephrine synthesis, was decreased. The differentiation potential of the cells was tested by treating cells from dissociated chromospheres with dexamethasone (Dex) or bone morphogenetic protein 4 (BMP-4). Expression of PNMT was up-regulated by Dex treatment. Upon treatment with BMP-4, cells showed neurite outgrowth and were positive for beta-III-tubulin immunostaining, a marker for neural differentiation.
In conclusion, we successfully cultured adrenomedullary chromospheres which contain chromaffin progenitor cells. These are able to self-renew and to differentiate into cells with chromaffin or neuronal characteristics. In addition to the elucidation of adrenomedullary development, these data may be relevant for the development of chromaffin cell tumors from adrenomedullary stem cells.
PF.37. Gene expression analysis of pheochromocytoma: searching for new pathways involved in the hereditary susceptibility Introduction: Phaeochromocytomas and paragangliomas are rare neuroendocrine tumours that usually cause secondary hypertension by oversecretion of catecholamines. Nowadays, it is widely accepted that 25-30% of patients carry a germline mutation in one of six susceptibility genes: SDHB, SDHC, SDHD, RET, VHL and NF1. Nevertheless, there are still some familial cases not associated with any predisposing gene. On the other hand, it has been described that SDH associated tumours share similar features to VHL tumours, but taking into account the genetic predisposition of SDHB tumours to malignancy, it would be interesting to know more about the differences between both classes. Aim: to identify the transcriptional profiles associated to each genetic group, in order to find new altered pathways specifically involved in them depending on the genetic alteration.
Methods:
We collected 65 genetically characterized frozen tumours: 7 SDHB, 1 SDHC, 4 SDHD, 11 RET, 13 VHL, 2 NF1, 3 familial cases without mutations and 24 sporadic tumours. The transcriptional profiles obtained using the s Agilent gene expression microarrays platform were subsequently analyzed with the r GEPAS bioinformatics package. Result and conclusion: The unsupervised clustering confirmed previous data (Dahia et al., 2005) : (1) VHL and SDHB tumours clustered together in a different branch than RET and NF1 cases; (2) all familial cases without mutations were grouped into the RET/NF1 cluster. Based on GO terms, we performed a functional enrichment analysis of significantly differentially expressed genes that allowed pointing to different pathways specifically involved in each class.
